GlassScriptPhysician profile
Pamela A Casey
NPI 1831598051
$2,997.26
in general payments reported to CMS, 2019-2025
16 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $258 · 2022: $673 · 2023: $1,024 · 2024: $588 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,066.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $668.23 | 2022-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $460.46 | 2022-2025 | Rexulti |
| Abbvie INC. | $371.62 | 2022-2024 | |
| Neurelis, INC. | $200.09 | 2021-2025 | Valtoco |
| Sanofi-Aventis U.S. LLC | $176.68 | 2022-2023 | |
| Novo Nordisk INC | $124.99 | 2023 | Wegovy |
| Urovant Sciences INC | $124.80 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $119.93 | 2023 | Crysvita |
| Neurocrine Biosciences, INC. | $118.02 | 2023 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $117.21 | 2023 | Quviviq |
| Boston Scientific Corporation | $112.16 | 2025 | Wavewriter Alpha Prime 16 |
| Axsome Therapeutics, INC. | $107.40 | 2024 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $104.08 | 2021 | |
| Jazz Pharmaceuticals INC. | $95.95 | 2022 | |
| Medtronic, INC. | $74.71 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $20.93 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Casey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.